• How Patient-Mediated Research Can Disrupt Life Sciences

    Clinical Research News | The life science industry is changing. There are growing calls for real-world evidence (RWE) and feedback from patients (PROs). Rare diseases are growing in importance, and there is increasing recognition of equity as an ethical and drug-efficacy necessity.

    May 10, 2024
  • Functional Precision Medicine Shows Promise for Kids With Tough Cancers

    Clinical Research News | A cancer researcher at Florida International University (FIU) has developed a functional precision medicine (FPM) approach to oncology treatment decision-making that combines genomic profiling with drug sensitivity testing on patient-derived tumor cells. Children with relapsed or refractory cancers are among the initial beneficiaries.

    May 9, 2024
  • Thermo Fisher on the Rise of Next-Generation Sequencing CDx

    Clinical Research News | In oncology, it is well appreciated that time is life. Diagnostics are therefore valuable not just to determine the disease state of patients but how best to treat them, says Jane Li, senior director of oncology, pharma, and CRO partnerships related to clinical sequencing at Thermo Fisher Scientific.

    May 7, 2024
  • eConsent In Decentralized Clinical Trials - A Path To Participant Empowerment And Transparency

    Clinical Research News | Electronic consent, or eConsent, has emerged as a cornerstone in the decentralized clinical trials (DCTs) landscape. Central to this is the Food and Drug Administration’s (FDA) resounding endorsement of electronic methodologies for obtaining informed consent from clinical trial participants.

    May 3, 2024
  • New Test Looks at Unique Response of MS Patients to Epstein-Barr Virus

    Clinical Research News | Significant evidence now exists implicating the Epstein-Barr virus (EBV) as a causal factor in the development of multiple sclerosis (MS), making treatment of the virus a priority. To that end, research scientists at Trinity College Dublin have developed a blood test to measure the immune response to EBV that could be used as an outcome measure in future clinical trials in people with established MS.

    May 1, 2024